Physician profile
Matthew Witte
NPI 1750940284
$4,083.75
in general payments reported to CMS, 2019-2025
21 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.51 · 2023: $591 · 2024: $2,142 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.37 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $538.91 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $466.56 | 2023-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $450.24 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.61 | 2024-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $284.22 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $216.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $187.24 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Exact Sciences Corporation | $113.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $111.70 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $82.73 | 2023-2024 | Gvoke Hypopen |
| Depuy Synthes Sales INC. | $50.71 | 2023-2025 | Orthovisc, Monovisc |
| Lundbeck LLC | $48.73 | 2025 | Vyepti |
| Pfizer INC. | $45.83 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.87 | 2024 | Veozah |
| Abbvie INC. | $26.16 | 2023 | Ubrelvy |
| Djo, LLC | $24.25 | 2025 | Aircast, Donjoy |
| Ferring Pharmaceuticals INC. | $18.08 | 2023 | Euflexxa |
| Axsome Therapeutics, INC. | $17.89 | 2025 | Auvelity |
| Boston Scientific Corporation | $14.99 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Witte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.